Overview
The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.
This year's conference was filled with major sessions dedicated to outcomes trials and Phase III programs, notably: first details from Trulicity's REWIND (LLY, Sumitomo Dainippon) cardiovascular outcomes trial (CVOT), first conference presentation of oral semaglutide's (NVO, EMIS) PIONEER 6 CV safety study and other trials from its Phase III program, first ADA presentation of Invokana's (JNJ, Mitsubishi Tanabe, Daiichi Sankyo) CREDENCE cardiorenal outcomes trial, an update with new CV and renal details from Farxiga's (AZN, Ono) DECLARE-TIMI 58 CVOT, first details from Tradjenta's (Boehringer, LLY) CAROLINA CVOT trial against glimepiride, and first ADA presentation of Tradjenta's CARMELINA CVOT against placebo.
The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.
This year's conference was filled with major sessions dedicated to outcomes trials and Phase III programs, notably: first details from Trulicity's REWIND (LLY, Sumitomo Dainippon) cardiovascular outcomes trial (CVOT), first conference presentation of oral semaglutide's (NVO, EMIS) PIONEER 6 CV safety study and other trials from its Phase III program, first ADA presentation of Invokana's (JNJ, Mitsubishi Tanabe, Daiichi Sankyo) CREDENCE cardiorenal outcomes trial, an update with new CV and renal details from Farxiga's (AZN, Ono) DECLARE-TIMI 58 CVOT, first details from Tradjenta's (Boehringer, LLY) CAROLINA CVOT trial against glimepiride, and first ADA presentation of Tradjenta's CARMELINA CVOT against placebo.
Table of Contents
Selected Abstracts Featured at the American Diabetes Association 79th Scientific Sessions..13
GLP-1 Co-Agonists
SGLT Inhibitors
DPP-IV Inhibitors48
Insulins
Prevention of Type 1 Diabetes
Non-Alcoholic Steatohepatitis (NASH)
Notes on Dyslipidemia
Other Mechanisms
Devices
